Meet the relatives: A reintroduction to the clinical pharmacology of 'typical' antipsychotics (part 1)

Advances in Psychiatric Treatment

Volumn 18, Issue 5, 2012, Pages 323-336

  Owens, David Cunningham ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENPERIDOL; BENZAMIDE; BUTYROPHENONE; CHLORPROMAZINE; CODEINE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERICIAZINE; PERPHENAZINE; PHENOTHIAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMAZINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; THIOXANTHENE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

AKATHISIA; BINDING AFFINITY; BLURRED VISION; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DROWSINESS; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HISTORY OF MEDICINE; HUMAN; HYPOTENSION; JAUNDICE; MEDICAL DECISION MAKING; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRESCRIPTION; PSYCHIATRIST; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT PLANNING; UNITED KINGDOM; XEROSTOMIA;

EID: 84867256599     PISSN: 13555146     EISSN: 14721481     Source Type: Journal    
DOI: 10.1192/apt.bp.109.006908     Document Type: Review

References (88)

1. Amaral L, Viveiros M, Kristiansen JE (2001) Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Tropical Medicine and International Health 6: 1016-22.
2. Andreasen NC, Pressler M, Nopoulos P, et al (2010) Antipsychotic dose equivalents and dose-years: a standardised method for comparing exposure to different drugs. Biological Psychiatry 67: 255-62.
3. Anonymous (1967) Today's drugs: pericyazine. BMJ 1: 352-53.
4. Atkins M, Burgess A, Bottomley C, et al (1997) Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatric Bulletin 21: 224-6.
5. Azima H, Durost H (1957) Comparison of the effects of promazine and chlorpromazine in mental syndromes. Canadian Medical Association Journal 77: 671-5.
6. Baldessarini RJ, Katz B, Cotton P (1984) Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry 141: 748-52.
7. Ban TA (1971) Drug treatment in schizophrenia. Canadian Psychiatric Association Journal 16: 473-84.
8. Barker JC, Miller M (1969) A double blind comparative trial of pericyazine and thioridazine in chronic schizophrenia. British Journal of Psychiatry 115: 169-72.
9. Becker RE (1981) Propericiazine: effectiveness against hostility and aggression as compared to chlorpromazine. Current Therapeutic Research 29: 925-8.
10. Bhargava KP, Chandra OM (1964) Tranquillizing and hypotensive activities of twelve phenothiazines. British Journal of Pharmacology 22: 154-61.
11. Bobon J, Bobon D, Pinchard A, et al (1972) A comparative physiognomy of neuroleptics: a collaborative clinical report. Acta Psychiatrica Belgica 72: 542-54.
12. Bugamelli F, Mandrioli R, Kenndler E, et al (2007) Possible levomepromazine-clozapine interaction: two case reports. Progress in Neuropsychopharmacology and Biological Psychiatry 31: 567-70.
13. British Medical Association, Royal Pharmaceutical Society (2012) British National Formulary (63 March). BMJ Group & Pharmaceutical Press.
14. Chew ML, Mulsant BH, Pollock BG, et al (2008) Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatric Society 56: 1333-41.
15. Davis JM (1976) Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 33: 858-61.
16. Davis JM, Chen N (2004) Dose response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 24: 192-208.
17. Denham J (1958) The use of prochlorperazine (Stemetil) in chronic psychotic disorders. Journal of Mental Science 104: 1190-4.
18. Dewan MJ, Koss M (1995) The clinical impact of reported variance in potency of antipsychotic agents. Acta Psychiatrica Scandinavica 91: 229-32.
19. DiMascio A, Havens LL, Klerman GL (1963a) The psychopharmacology of phenothiazine compounds: a comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males. 1: Introduction, aims and methods. Journal of Nervous and Mental Disease 136: 15-28.
20. DiMascio A, Havens LL, Klerman GL (1963b) The psychopharmacology of phenothiazine compounds: a comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males. II. Results and discussion. Journal of Nervous and Mental Disease 136: 168-86.
21. Dransfield GA (1958) A clinical trial comparing prochlorperazine ('Stemetil') with chlorpromazine ('Largactil' ) in the treatment of chronic psychotic patients. Journal of Mental Science 104: 1183-9.
22. Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacology and Therapeutics 57: 1-78.
23. Feldkamp MD, O'Donnell SE, Yu L, et al (2010) Allosteric effects of the antipsychotic drug trifluoperazine on the energetics of calcium binding by calmodulin. Proteins 78: 2265-82.
24. Finn A, Collins J, Voyksner R, et al (2005) Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route. Journal of Clinical Pharmacology 45: 1383-90.
25. Fischer-Barnicol D, Lanquillon S, Haen E, et al (2008) Typical and atypical antipsychotics - the misleading dichotomy. Results from the Working Group 'Drugs and Psychiatry' (AGATE). Neuropsychobiology 57: 80-7.
26. Fischer-Cornelsson K, Ferner U, Steiner H (1974) Multifokale Psychopharmakaprufung [Multi-hospital trial]. Arzneimittelforschung 24: 1706-24.
27. Fleming BG, Spencer AM, Whitelaw EM (1959) A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis. Journal of Mental Science 105: 349-58.
28. Fleming FF, Yao L, Ravikumar PC, et al (2010) Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. Journal of Medicinal Chemistry 53: 7902-17.
29. Frain MK (1957) Promazine treatment of chronic psychoses in 100 hospitalised patients. Journal of Nervous and Mental Disease 125: 529-33.
30. Gardner DM, Murphy AL, O'Donnell H, et al (2010) International consensus study of antipsychotic dosing. American Journal of Psychiatry 167: 686-93.
31. Gwynne PH, Hundziak M, Kavtschitsch J, et al (1962) Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease 134: 451-5.
32. Hansen CE, Christensen TR, Elley J, et al (1976) Clinical pharmacokinetic studies of perphenazine. British Journal of Clinical Pharmacology 3: 915-23.
33. Harrison-Read PE (2009) Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors - a new analysis of data from the archives and implications for improved antimanic treatments. Journal of Psychopharmacology 23: 899-907.
34. Hartung B, Wada M, Laux G, et al (2005) Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews issue 1: CD003443 (doi: 10.1002/14651858. CD003443.pub2).
35. Healy D (1996) The Psychopharmacologists. Chapman and Hall.
36. Heller GC, Mather MD (1965) [Untitled]. In Proceedings of the Leeds Symposium on Behavioural Disorders 25-27 March 1965 (eds FA Jenner, P Hays): 80. May & Baker.
37. Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA (1983) Trifluoperazine and chlorpromazine antagonise alpha-1 but not alpha-2 adrenergic effects. Molecular Pharmacology 23: 67-70.
38. Hyttel J, Larsen J-J, Christensen AV, et al (1985) Receptor-binding profiles of neuroleptics. In Dyskinesia: Research and Treatment (eds DE Casey, TN Chase, AV Christensen, et al): 9-18. Springer-Verlag.
39. Isah AO, Rawlins MD, Bateman DN (1991) Clinical pharmacology of prochlorperazine in healthy young males. British Journal of Clinical Pharmacology 32: 667-84.
40. Jenner FA, Hays P, Flynn P (eds) (1965) Proceedings of the Leeds Symposium on Behavioural Disorders. May and Baker.
41. Jones PB, Barnes T, Davis L, et al (2006) Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry 63: 1079-87.
42. Kahn R, Fleischhacker WW, Boter H, et al (2008) The European First Episode Schizophrenia Trial (EUFEST). Lancet 371: 1085-97.
43. Kane J, Honigfeld G, Singer J, et al (1988) Clozapine for the treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789-96.
44. Kane JM, Leucht S, Carpenter D, et al (2003) Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Journal of Clinical Psychiatry 64 (suppl 12): 5-19.
45. Klerman GL (1974) Pharmacotherapy of schizophrenia. Annual Review of Medicine 25: 199-217.
46. Lal S, Nair NPV (1992) Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatrica Scandinavica 85: 243-5.
47. Lal S, Nair NPV, Cecyre D, et al (1993) Levomepromazine receptor binding profile in human brain: implications for treatment resistant schizophrenia. Acta Psychiatrica Scandinavica 87: 380-3.
48. Lal S, Thavundayil JX, Nair NP, et al (2006) Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized study. Journal of Psychiatry and Neuroscience 31: 271-9.
49. Leucht S, Kissling W, Davis JM (2009) Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychological Medicine 39: 1591-602.
50. Lieberman JA, Stroup TS, McEvoy JP, et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-23.
51. Linnoila M, George L, Guthrie S (1982) Interaction between antidepressants and perphenazine in psychiatric inpatients. American Journal of Psychiatry 139: 1329-31.
52. Macdonald R, Watts TPS (1959) Trifluoperazine dihydrochloride ('Stelazine') in paranoid schizophrenia. BMJ 1: 549-50.
53. Madgwick JRA, McNeill DLM, Driver M, et al (1958) Stelazine (trifluoperazine): a preliminary report on a clinical trial. Journal of Mental Science 104: 1195-8.
54. Mangun CW, Webb WW (1956) Promazine hydrochloride in the treatment of chronic catatonic schizophrenics. Journal of Nervous and Mental Disease 123: 553-6.
55. Marques LDO, Soares B, Silva de Lima M (2004) Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews issue 1: CD003545 (doi: 10.1002/14651858.CD003545.pub2).
56. Matar HE, Almerie MQ, Makhoul S, et al (2008) Pericyazine for schizophrenia. Cochrane Database of Systematic Reviews issue 4: CD007479 (doi: 10.1002/14651858.CD007479).
57. Midha KK, Korchinski ED, Verbeeck RK, et al (1983) Kinetics of oral trifluoperazine disposition in man. British Journal of Clinical Pharmacology 15: 380-2.
58. Midha KK, Hawes EM, Hubbard JW, et al (1988) A pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacology 95: 333-8.
59. Milne HB, Berliner F (1958) A clinical trial of Stemetil (prochlorperazine). Journal of Mental Science 104: 873-9.
60. Milne HB, Fowler DB (1960) A clinical trial of Largactil (chlorpromazine), Stemetil (prochlorperazine) and Veractil (methotrimeprazine). Journal of Mental Science 106: 1105-10.
61. Motohashi N (1991) Phenothiazines and calmodulin (review). Anticancer Research 11: 1125-64.
62. Motohashi N, Kawase M, Satoh K, et al (2006) Cytotoxic potential of phenothiazines. Current Drug Targets 7: 1055-66.
63. Musey VC, Preedy JR, Musey PI, et al (1986) Prolactin and blood pressure responses to perphenazine in human subjects: comparison of the oral and intramuscular routes. American Journal of the Medical Sciences 291: 380-5.
64. Naber D, Lambert M (2009) The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23: 649-59.
65. Owens DGC (1999) A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge University Press.
66. Owens DGC (2008) How CATIE brought us back to Kansas: a critical reevaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Advances in Psychiatric Treatment 14: 17-28.
67. Owens DGC (2010) Clinical psychopharmacology. In Companion to Psychiatric Studies (8th edn) (eds EC Johnstone, DGC Owens, SM Lawrie, et al): 227-94. Churchill Livingstone.
68. Owens DGC (2012) Meet the relatives: an reintroduction to the clinical pharmacology of 'typical' antipsychotics (Part 2). Advances in Psychiatric Treatment 18: 337-50.
69. Ozdemir V, Naranjo CA, Herrmann N, et al (1997) Paroxetine potentiates the central nervous system side-effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo. Clinical Pharmacology and Therapeutics 62: 334-47.
70. Payne P (1959) Trifluoperazine in treatment of the acutely ill psychotic: a preliminary report. Canadian Medical Association Journal 81: 42-3.
71. Payne P, Verinder D (1960) Levomepromazine in the treatment of neuroleptic resistant psychotics. Journal of Mental Science 106: 1429-31.
72. Rees L (1960) Chlorpromazine and allied phenothiazine derivatives. BMJ 2: 522-5.
73. Rey M-J, Schulz P, Costa C, et al (1989) Guidelines for the dosage of neuroleptics. 1: Chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology 4: 95-104.
74. Roth BL, Craigo SC, Choudhary MS, et al (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. Journal of Pharmacology and Experimental Therapeutics 268: 1403-10.
75. Sarwer-Foner GJ, Koranyi EK, Mackay J, et al (1959) Clinical investigation of trifluoperazine (Stelazine) in open psychiatric settings. Canadian Medical Association Journal 81: 717-23.
76. Schreinzer D, Frey R, Stimpfl T, et al (2001) Different fatal toxicity of neuroleptics identified at autopsy. European Neuropsychopharmacology 11: 117-24.
77. Sikich L, Frazier JA, McClellan J, et al (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry 165: 1420-31.
78. Simpson RW, Jesson JG (1958) The effects of promazine ('Sparine') in chronic schizophrenia. Journal of Mental Science 104: 1199-202.
79. Sudeshna G, Parimal K (2010) Multiple non-psychiatric effects of phenothiazines: a review. European Journal of Pharmacology 648: 6-14.
80. Swazey JP (1974) Chlorpromazine in Psychiatry: A Study of Therapeutic Innovation. MIT Press.
81. Sweet RA, Pollock BG, Mulsant BH, et al (2000) Pharmacologic profile of perphenazine's metabolites. Journal of Clinical Psychopharmacology 20: 181-7.
82. Tatsumi M, Jansen K, Blakely RD, et al (1999) Pharmacological profile of neuroleptics at human monoamine transporters. European Journal of Pharmacology 368: 277-83.
83. Thanacoody HKR (2007) Thioridazine: resurrection as an antimicrobial agent? British Journal of Clinical Pharmacology 64: 566-74.
84. Vevelstad M, Pettersen S, Tallaksen C, et al (2009) O-demethylation of codeine to morphine is inhibited by low-dose levomepromazine. European Journal of Clinical Pharmacology 65: 795-801.
85. Wilson IC, McKay J, Sandifer MGR (1961) A double-blind trial to investigate the effects of Thorazine (Largactil, chlorpromazine), Compazine (Stemetil, prochlorperazine) and Stelazine (trifluoperazine) in paranoid schizophrenia. Journal of Mental Science 107: 90-9.
86. Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64: 663-7.
87. Wyatt RJ (1976) Biochemistry and schizophrenia (part IV): the neuroleptics - their mechanisms of action: a review of biochemical literature. Psychopharmacology Bulletin 12: 5-50.
88. Yoshimura R, Shinkai K, Kakihara S, et al (2005) Little effect of low dosage of levomepromazine on plasma risperidone levels. PharmacoPsychiatry 38: 98-100.